focus -WSS

focus

author：fashion 2025-09-30 06:21:54 - browse：18

The Food and Drug Administration on Friday approved the world’s first medicine based on CRISPR gene-editing technology, a groundbreaking treatment for sickle cell disease that delivers a potential cure for people born with the chronic and life-shortening blood disorder.

The new medicine, called Casgevy, is made by Vertex Pharmaceuticals and CRISPR Therapeutics. Its authorization is a scientific triumph for the technology that can efficiently and precisely repair DNA mutations — ushering in a new era of genetic medicines for inherited diseases.

In a clinical trial, Casgevy was shown to eliminate recurrent episodes of debilitating pain caused by sickle cell, which afflicts approximately 100,000 people in the U.S., a vast majority of whom are Black. The therapy, whose scientific name is exa-cel, is described as a potential cure because the genetic fix enabled by CRISPR is designed to last a lifetime, although confirmation will require years of follow-up.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： 'Weather

leisure time

WSS

Bernie Sanders gets little from pharma CEOs on drug prices

Russian and Belarusian players banned from a women's tennis tournament in Prague

Tome Biosciences co

Adidas to release second batch of Yeezy sneakers after breakup with Ye

Many immigrants are left out of maternal health programs

House GOP plan to stem drug shortages differs from Democrats’

hotspot

focus

leisure time

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Having children helps parents live longer, especially after age 80

At least 13 dead in Texas as scorching temps continue

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

Continuity nursing helped my family in our darkest PICU moments

Why don't Americans have at

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Malaria cases in Florida and Texas: Here’s what you need to know

Ebola vaccine can save some who are already sick, per new study

hotspot

What AstraZeneca

ACIP vaccine advisory panel sees its vacancies filled

Juul documents reveal insider tactics on political lobbying

Juul documents reveal insider tactics on political lobbying

Here’s what’s in the FDA plan to include pregnant women in clinical trials

House GOP plan to stem drug shortages differs from Democrats’

leisure time

focus

focus

knowledge